D
19.23
-0.06 (-0.31%)
| Penutupan Terdahulu | 19.29 |
| Buka | 19.41 |
| Jumlah Dagangan | 942,634 |
| Purata Dagangan (3B) | 1,774,216 |
| Modal Pasaran | 3,049,714,176 |
| Harga / Jualan (P/S) | 3.64 |
| Harga / Buku (P/B) | 3.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 May 2026 |
| EPS Cair (TTM) | -2.64 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.59% |
| Nisbah Semasa (MRQ) | 9.56 |
| Aliran Tunai Operasi (OCF TTM) | -365.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -257.54 M |
| Pulangan Atas Aset (ROA TTM) | -22.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Denali Therapeutics Inc. | Menaik | Menurun |
AISkor Stockmoo
-0.1
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.86% |
| % Dimiliki oleh Institusi | 94.15% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Temasek Holdings (Private) Ltd | 31 Dec 2025 | 7,012,974 |
| Julat 52 Minggu | ||
| Median | 36.00 (87.21%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 02 Mar 2026 | 36.00 (87.21%) | Beli | 21.00 |
| 06 Feb 2026 | 32.00 (66.41%) | Beli | 21.08 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |